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Since most published epidemiological data on IBD origi-
nates from Western countries, it remains to be determined 
whether data published in the West can be directly trans-
lated to the Asian setting. In particular, there is a pressing 
need to validate whether the disease phenotypes, responses 
to various treatments, and complications are comparable 
between Asian patients and their Western counterparts. 
To this end, our Asian colleagues have produced many 
high-quality publications on the epidemiology of IBD in 
Asia. A simple search of the PubMed (as in April 2015) data-
base with the keyword “IBD epidemiology in Asia” yields an 
increasing number of publications over the past few decades 
(Fig. 1). There were virtually no publications on this topic 
before the 70’s, followed by a surge in the late 90’s. However, 
many of these studies, particularly the early ones, involved 
small numbers of patients and were based on a few highly 
selected tertiary referral centers in Asia, which may limit the 
validity of the results when generalized to the broader re-
gion.
SPECIAL REVIEW: IBD and Epidemiology in Asia
INTRODUCTION
The incidence of IBD has been rising rapidly globally over 
the past few decades.1 There are wide geographic variations 
in the incidence and prevalence of IBD, and the disease is 
still more prevalent in Western countries than in Asia. In 
Asia, IBD is a rapidly emerging disease, particularly in the 
more developed countries of the region.2,3 A recent multi-
country epidemiological study showed that the incidences 
of both CD and UC are still significantly lower in most Asian 
countries than in Australia.4 However, there are wide varia-
tions in the incidence of IBD across different Asian coun-
tries.
© Copyright 2015. Korean Association for the Study of Intestinal Diseases. All rights reserved.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
ISSN 1598-9100(Print) • ISSN 2288-1956(Online)
http://dx.doi.org/10.5217/ir.2015.13.3.208
Intest Res 2015;13(3):208-212
Optimization of Inflammatory Bowel Disease Cohort 
Studies in Asia
Wai K. Leung
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong
With the incidence of inflammatory bowel disease (IBD) increasing rapidly in many Asian countries, including Hong Kong, it 
is important that patient characteristics are better understood. For example, are the phenotypes, behaviors, complications, and 
even treatment responses found in Asian patients similar to those of their Western counterparts? To formally address these 
questions, a properly designed local cohort study is needed. Whilst IBD is still relatively uncommon in Asia, the establishment 
of a local IBD registry will significantly contribute to the answering of these questions. The Hong Kong IBD registry was estab-
lished to fill the gap in the understanding of IBD patients, and to foster research into IBD in Hong Kong. The Hong Kong IBD 
registry is a territory-wide registry that includes all public hospitals in Hong Kong. We included all IBD patients who were cur-
rently receiving medical care at these hospitals. With the help of the central computer medical record system of the Hospital 
Authority of Hong Kong, all clinical events, medications usage, endoscopy records, and laboratory results of patients in the reg-
istry were captured. Apart from data collection, the registry is also establishing a bio-specimen bank of blood and stool samples 
of IBD patients for future research. The IBD registry is a very useful platform for population-based studies on IBD in Asia. 
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With the increasing number of IBD patients in Asia, better 
design and organization of epidemiological cohort studies 
are needed. This article attempts to discuss ways of optimiz-
ing IBD cohort studies, and to share our early experiences of 
the recently established Hong Kong IBD registry. 
AIMS OF COHORT STUDIES
Similar to randomized controlled studies, cohort studies 
are designed to address clinical questions relevant to disease 
pathogenesis, characteristics, or management. For IBD, com-
mon goals of cohort studies are to characterize epidemio-
logical data on IBD patients, and to collect information on 
treatment responses and disease related complications and 
health care utilization. They are also useful in determining 
other aspects of disease, including various social and psy-
chological parameters. 
Prospective cohort studies are capable of obtaining bio-
specimens such as colonic biopsy and fecal or blood sam-
ples for use in biobanks, which are very useful in subsequent 
genome-wide association studies as well as microbiota 
analyses.
COHORT STUDY DESIGN
Cohort studies are a form of longitudinal study that attem-
pts to analyze target outcomes in a group of individuals. The 
outcomes can be the occurrence of a target disease among 
those with exposure to certain risk factors, or the develop-
ment of a complication among those with a certain disease. 
In either case, the incidence of disease or the relative risk of 
exposure can be precisely estimated. In contrast to prospec-
tive randomized clinical trials that usually involve interven-
tion, cohort studies are usually observational in nature and 
patients are not randomly assigned to a specific treatment. 
This aspect is inferior to randomized controlled trials, as this 
approach may introduce bias. 
The design of these observational studies could be further 
classified into “prospective” and “retrospective”. For instance, 
a prospective IBD cohort enrolls all eligible IBD patients and 
follows them longitudinally. All relevant clinical and epide-
miological information is recorded at baseline, and updated 
at intervals during the follow-up period. This may limit recall 
bias when compared to retrospective cohort studies when 
the target outcome has already developed. However, some 
information collected is still retrospectively recalled, par-
ticularly in patients with longstanding disease. An inception 
cohort captures all patients newly diagnosed with IBD only, 
which minimizes these potential recall biases due to long lag 
times. This is extremely useful for epidemiological studies 
designed to determine incidence and exposure. Due to the 
prospective nature of these studies, they can provide accu-
rate relative risk or risk ratio estimation of target outcomes. 
Unlike randomized trials that typically assess a single prima-
ry outcome, multiple outcomes can be measured. However, 
inception cohort studies usually require long follow-up peri-
ods, and are generally expensive. Problems with patients be-
ing lost to follow-up can create uncertainties in data analysis 
and potential bias.
A retrospective cohort study is conceived after some indi-
viduals have already developed the outcomes, e.g., the occur-
rence of IBD or its related complications. This type of study 
does not require long follow-up duration and is particularly 
useful for rare diseases, such as IBD in Asia. These studies 
are also less costly than prospective cohort studies. Unlike 
in prospective studies, temporal relationships usually can-
not be determined. It is also important to adjust for potential 
confounding factors in retrospective cohort studies, particu-
larly in selecting cases and determining exposures.
IMPLEMENTATION OF PROSPECTIVE COHORT 
STUDIES
Although intervention is usually lacking for cohort stud-
ies, the design and execution, particularly for a prospective 
cohort study, is very similar to a randomized controlled 
trial. The effort and resources needed for this kind of study 
would be comparable to a prospective interventional study. 
A good example of a long-term cohort study is the Framing-
ham Heart Study, which was started in 1948.5 There are also 
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Fig. 1. Number of publications in PubMed on the epidemiology of IBD 
in Asia.
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many examples of long-term IBD cohort studies present in 
the literature (Table 1).6-15 Although most of these data are 
from Western countries, there are a few ongoing Asian co-
hort studies.4,16
 
1. Data Collection
In prospective IBD cohort studies, like inception cohort 
studies, all patients are identified at baseline and are fol-
lowed-up longitudinally for target outcomes like the devel-
opment of complications, mortality, surgical resection etc. 
Unfortunately, some of these target outcomes may not be 
identified at the beginning of the study, and are sometimes 
only considered many years after the study has started. 
Hence, it is vital to carry out comprehensive and detailed 
planning for baseline data collection. How often this infor-
mation needs to be updated is equally important. Since the 
frequency and extent of follow-up data collection can have 
major implications on resources and patient compliance, it 
is prudent to be realistic and practical. Due to the differences 
in health care systems in different countries, the availability 
of centralized electronic medical record systems or other 
similar administrative databases helps to reduce the work-
load of database maintenance. With long anticipated follow-
up durations, mechanisms should be in place to identify 
patients who have been lost to follow-up due to various rea-
sons. 
2. Resources
A team of dedicated IBD researchers is the most important 
asset of any IBD cohort study. This team should comprise 
gastroenterologists with a special interest in IBD, research 
assistants, biostatisticians, technicians, and other related 
health care personnel. With the many parties involved, 
regular meetings and progress reports are needed to update 
all members. A transparent and pre-defined mechanism of 
sharing the intellectual property obtained from this kind of 
cohort study, like authorships in publications and the share 
of patents, is also crucial to maintaining team spirit and 
avoiding future conflicts. It may also be necessary to estab-
lish a publication subcommittee to oversight all research-
Table 1. Examples of Population-Based IBD Registries 
Continent Reference Name of registry Countries Design Year No. of patients
Europe
6 Epimad registry Northern France Inception cohort 1988 18,170
7 EC-IBD study group Europe and Israel Inception cohort 1991 1,145
8 Danish CD database Denmark Prospective 2003 562
9 Swiss IBD cohort study group Switzerland Prospective 2003 1,020
10 CESAME study group France Prospective 2004 19,486
11 Cardiff UK Retrospective 1986-2003 341
12 SPIRIT registry Spain Retrospective 1996-2009 2,107 children
North America
13 University of Manitoba IBD  
   research registry
Canada Retrospective 1985 NA
14 Veterans Affairs USA Retrospective 1998-2009 43,114
15 ImproveCareNow Collaborative  
   for pediatric IBD
USA Multi-center registry 2007-2008 1,598 children
Asia-Pacific
16 Japanese nationwide IBD registry Japan Prospective 1975 NA
4 ACCESS study group Asia-Pacific Inception cohort 2011 419
Hong Kong IBD registry Hong Kong Prospective 2013 2,220
EPIMAD, registre des maladies inflammatoires du tube digestif du nord-ouest de la France; EC-IBD, European collaborative study group of 
inflammatory bowel disease; CESAME, cancers et surrisque associé aux maladies inflammatoires intestinales en France; SPIRIT, sociedad española de 
gastroenterología hepatología nutrición pediátrica; ACCESS, Asia-pacific crohn's and colitis epidemiology study; NA, not available.
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related publications. The long-term storage of bio-specimens 
requires proper designated storage space (or freezers) and 
staff, which can have long-term implications on resource 
utilization. It is also important to clearly define the rules and 
regulations governing the future usage of these bio-speci-
mens at the beginning of the study. 
As mentioned previously, obtaining adequate funding is 
another important task for investigators. With the long fol-
low-up duration (sometimes up to a few decades) of cohort 
studies, the provision of continuous funding support can be 
a problem for many non-governmental sponsored registries. 
Hence, a realistic estimate of the sustainability of this cohort 
study and a frequent revision of the budget may be neces-
sary, particularly for prospective cohort studies. 
3. Regulatory Issues
To ensure compliance with various regulatory authorities, 
approval from all local institutional review boards concerned 
should be obtained prior to the implementation of the study. 
This process can be very time consuming when multiple 
institutions are involved. Proper informed consent should 
also be obtained for patients enrolling in prospective studies, 
and particularly for studies involving the storage of patients’ 
clinical specimens. Special attention should also be directed 
to maintaining patients’ confidentially in the database. In-
ternet security is another important issue that should not 
be overlooked, particularly with the use of open web-based 
databases. However, the use of anonymous data may pose 
problems in subsequent follow-up and data validation. 
THE HONGKONG IBD REGISTRY
The Hong Kong IBD Registry was established in 2011 to 
systematically collect clinical and epidemiological data from 
IBD patients attending public hospitals in Hong Kong. The 
registry aims to fill the knowledge gap in the understanding 
of IBD patients and foster IBD research in Hong Kong. It is 
a territory-wide registry that includes all public hospitals in 
Hong Kong. The public hospital system is directly funded 
by the Hong Kong Government, and is available to all local 
residents at a minimal cost. It currently provides more than 
90% of in-patient services in Hong Kong. The current registry 
covers 13 public hospitals with a catchment area of more 
than 7.3 million people. The registry was approved by the 
local Institutional Review Boards (IRBs) of each individual 
hospital. Funding was provided by local philanthropists and 
the pharmaceutical industry, both of which have no role in 
the daily operations of the registry. A central web-based da-
tabase was used for data entry from individual participating 
hospitals. All patients were provided with a unique patient 
number such that no confidential patient information was 
stored in the central database. 
We prospectively enrolled all patients with a confirmed di-
agnosis of IBD including CD, UC, and indeterminate colitis. 
With the help of the central computer medical record system 
of the Hospital Authority of Hong Kong, which essentially 
captured all clinical events, prescription histories, endos-
copy records, and laboratory results of these patients, im-
portant clinical information could be updated periodically. 
As of April 2014, we collected information from more than 
2,200 IBD patients. Results of some of the baseline analyses 
of these patients were presented in Digestive Disease Week 
2015. Apart from data collection, the registry is also setting 
up a bio-specimen bank of blood and stool samples of IBD 
patients for future genomic and microbiota studies. 
CONCLUSIONS
It is an exciting moment for IBD research in the Asia Pa-
cific region, where the disease is emerging rapidly. The for-
mation of IBD study groups and local IBD registries would 
help to produce valuable epidemiological data on patients, 
and will ultimately help to transform the care of IBD patients 
in this region. 
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